Paul Grayson

Paul joined Versant in 2017. In addition to his reputation as a deal-maker, Paul brings a wealth of operating and investment experience from a successful career in the biotech sector spanning 25 years. He specializes in start-up through IND enablement, CMC and clinical proof of concept stage products.

Paul also is president and CEO of La Jolla-based Bird Rock Bio, a Versant portfolio company focused on fibrotic, metabolic and inflammatory diseases. Prior to joining Bird Rock Bio, Paul was the founding CEO of Fate Therapeutics (NASDAQ:FATE) a clinical-stage, next-generation cellular immunotherapy company.